Skip to main content
. Author manuscript; available in PMC: 2016 Jul 26.
Published in final edited form as: Nature. 2015 May 27;522(7554):106–110. doi: 10.1038/nature14492

Extended Data Figure 3. Additional patient data analysis in a supporting patient cohort.

Extended Data Figure 3

a, ROC curve analysis shows LOX expression may be indicative of metastatic dissemination of ER-negative breast cancer (AUC 0.77, P<0.0001) but not ER-positive patients (AUC 0.55, P<0.1504). b, In an alternative second patient dataset (Van de Vijver et al. [pubmed ID: 12490681]) reporting data on 295 lymph node negative (LNN) patients who did not receive adjuvant therapy, with available site of relapse, LOX is significantly higher expressed in bone relapse ER-negative patients, compared to other groups confirming data from the original dataset.